Educational information, not medical advice — ask your doctor or midwife.
Pushyanug Churna is a time-honored Ayurvedic compound herbal powder first described in classical texts such as the Ashtanga Hridayam and the Sharangadhara Samhita. It brings together more than 20 astringent, anti-inflammatory, and hormone-supportive herbs, working as a team rather than relying on a single active compound. The formula is specifically designed for conditions the Ayurvedic tradition groups under 'Raktapradara' (excessive uterine bleeding) and 'Shwetapradara' (leucorrhea).
The majority of herbs in the blend — including Lodhra, Ashoka, Jambu, and Amra bark — are rich in tannins and polyphenols that help tighten and tone the uterine lining and reduce excessive blood loss. Ashoka bark in particular has been studied for compounds that may support normal hormonal balance and reduce uterine muscle spasm. Supporting herbs like Shatavari and Anantamula add an adaptogenic, anti-inflammatory dimension that helps address the root hormonal and tissue imbalances driving these symptoms.
The traditional form is a fine herbal powder (churna) taken with honey, rice water, or warm water. Modern formulations are also available as capsules or compressed tablets for convenience, though traditional texts favor the powder form for faster absorption and synergy with the carrier medium.
Pushyanug Churna is formally listed in the Ayurvedic Formulary of India (AFI) — the official government reference for classical Ayurvedic preparations — and has been prescribed by Ayurvedic physicians for centuries to address female reproductive complaints. Its name references the Pushya nakshatra (a lunar asterism considered auspicious for medicine in Vedic tradition), and the formula appears in multiple classical Samhita texts spanning at least 1,000 years of documented use.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.